Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Naser Kalani Yazd

Nurse Practitioner, Family Denver, CO Nurse Practitioner

NPI 1326064726 CMS profile 11021480

6850 E Evans Ave, Suite 102, Denver, CO 80224

Open in the dashboard

General payments

$15,205

664 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Naser Kalani Yazd of Denver, CO is reported in the CMS Open Payments database as having received $15,205 across 664 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,697 131
2024 General $2,549 106
2023 General $3,111 118
2022 General $3,056 149
2021 General $2,793 160

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Naser Kalani Yazd
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Naser Kalani Yazd were reported at $3,697. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Naser Kalani Yazd Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $2,793 $124 $35–$379 $132
2022 $3,056 $141 $44–$430 $149
2023 $3,111 $154 $49–$476 $160
2024 $2,549 $165 $51–$504 $164
2025 $3,697 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $2,669 66 payments
  2. AbbVie, Inc. $2,112 73 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,846 127 payments
  4. Novo Nordisk Inc $1,081 44 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $823 38 payments
  6. Sumitomo Pharma America, Inc. $535 22 payments
  7. Neurocrine Biosciences, Inc. $526 13 payments
  8. Teva Pharmaceuticals USA, Inc. $483 14 payments
  9. ITI, Inc. $467 29 payments
  10. Novartis Pharmaceuticals Corporation $426 26 payments
  11. Other $4,236 212 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,947 657 payments
  2. Education $244 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14 1 payment
Products named General payments · program years 2021–2025
  1. TRULANCE $1,181 83 payments
  2. BREZTRI $1,036 17 payments
  3. XIFAXAN $928 72 payments
  4. Kerendia $823 38 payments
  5. FARXIGA $749 16 payments
  6. VRAYLAR $641 21 payments
  7. UBRELVY $609 17 payments
  8. GEMTESA $599 26 payments
  9. CREON $571 22 payments
  10. QULIPTA $557 16 payments
  11. Other $11,849 557 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 161 drugs

Part D claims

8,862

Median for Nurse Practitioner: 389

Drug cost

$1,281,850

Median for Nurse Practitioner: $21,885

Branded share of claims

26.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trulicity Dulaglutide Brand 141 $146,237
Mounjaro Tirzepatide Brand 113 $125,900
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 108 $84,008
Xarelto Rivaroxaban Brand 96 $72,162
Trulance Plecanatide Brand 102 $68,508
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 87 $59,658
Farxiga Dapagliflozin Propanediol Brand 72 $53,573
Eliquis Apixaban Brand 69 $51,406
Zenpep Lipase/Protease/Amylase Brand 17 $49,552
Linzess Linaclotide Brand 68 $43,832

The 10 drugs with the highest cost, of 161 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$181,366

Of which drugs: $216

Medicare patients

502

Average age 67

Services billed

4,460

214 women, 288 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 72%
Arthritis 40%
Chronic kidney disease 39%
Depression 37%
COPD 25%
Alzheimer's or dementia 19%
Ischemic heart disease 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 72 195 $175

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 34 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $283
$283 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $219
$219 — —
Wegovy
  • Novo Nordisk Inc $206
$206 — —
LINZESS
  • AbbVie, Inc. $149
  • Ironwood Pharmaceuticals, Inc $14
$163 68 —
QULIPTA
  • AbbVie, Inc. $161
$161 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 34 with Patron

Records

664 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Colorado

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record